ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus …
…, HW Farber, JR Lindner, MA Mathier, MD McGoon… - Circulation, 2009 - Am Heart Assoc
Pulmonary hypertension (PH) is a complex, multidisciplinary disorder. Recent advances
have led to increased recognition and new therapies. While some data exist to form …
have led to increased recognition and new therapies. While some data exist to form …
Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure
…, RA Quaife, LA Leinwand, RJ Barst, MD McGoon… - Circulation, 2006 - Am Heart Assoc
Knowledge about the role of the right ventricle in health and disease historically has lagged
behind that of the left ventricle. Less muscular, restricted in its role to pumping blood through …
behind that of the left ventricle. Less muscular, restricted in its role to pumping blood through …
Pulmonary arterial hypertension
VV McLaughlin, MD McGoon - Circulation, 2006 - Am Heart Assoc
… Dr McGoon has received research grant support from CoTherix, Glaxo-Wellcome, Medtronic,
Myogen, Pfizer, and United Therapeutics; serves on a Steering Committee for CoTherix; …
Myogen, Pfizer, and United Therapeutics; serves on a Steering Committee for CoTherix; …
[HTML][HTML] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
…, LJ Rubin, WA Long, MD McGoon… - … England Journal of …, 1996 - Mass Medical Soc
Background Primary pulmonary hypertension is a progressive disease for which no treatment
has been shown in a prospective, randomized trial to improve survival. Methods We …
has been shown in a prospective, randomized trial to improve survival. Methods We …
[HTML][HTML] Valvular heart disease associated with fenfluramine–phentermine
HM Connolly, JL Crary, MD McGoon… - … England Journal of …, 1997 - Mass Medical Soc
Background Fenfluramine and phentermine have been individually approved as anorectic
agents by the Food and Drug Administration (FDA). When used in combination the drugs may …
agents by the Food and Drug Administration (FDA). When used in combination the drugs may …
Primary pulmonary hypertension: natural history and the importance of thrombosis.
…, PM Steele, WD Edwards, BJ Gersh, MD McGoon… - Circulation, 1984 - Am Heart Assoc
A long-term retrospective follow-up study was made of 120 patients (33 male, 87 female
patients) with primary pulmonary hypertension--diagnosed by strict clinical and hemodynamic …
patients) with primary pulmonary hypertension--diagnosed by strict clinical and hemodynamic …
Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management …
…, DB Badesch, CG Elliott, TG Liou, MD McGoon - Circulation, 2010 - Am Heart Assoc
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …
clinical management. A quantitative survival prediction tool has not been established for …
The natural history of lone atrial fibrillation
SL Kopecky, BJ Gersh, MD McGoon… - … England Journal of …, 1987 - Mass Medical Soc
From 1950 to 1980, 3623 patients from Olmsted County, Minnesota, were found to have atrial
fibrillation. Ninety-seven of these patients (2.7 percent), who were 60 years old or younger …
fibrillation. Ninety-seven of these patients (2.7 percent), who were 60 years old or younger …
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
…, S Giles, K Feldkircher, DP Miller, MD McGoon - Chest, 2010 - Elsevier
Background The Registry to EValuate Early And Long-term pulmonary arterial hypertension
disease management (REVEAL Registry) was established to provide updated …
disease management (REVEAL Registry) was established to provide updated …
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial
DB Badesch, VF Tapson, MD McGoon… - Annals of internal …, 2000 - acpjournals.org
Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …
scleroderma spectrum of disease for which no treatment has been proven effective in a …